EXAS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Exact Sciences Corp is not a strong buy at the moment for a beginner investor seeking long-term growth. While the company has positive catalysts such as its acquisition by Abbott and its partnership with Walgreens, the financial performance shows significant declines in net income and EPS. Additionally, hedge funds are selling, and there is no strong technical or proprietary trading signal to suggest an immediate entry point. The stock is better suited for monitoring rather than immediate investment.
The stock's moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the MACD histogram is negative and contracting, and the RSI is neutral at 65.677. The price is trading near its pivot level of 103.614, with minor resistance at 103.914 and support at 103.314. Overall, the technical indicators do not suggest a strong buy signal.
Abbott's acquisition of Exact Sciences for $21 billion enhances its diagnostic business, particularly with the Cologuard product. Walgreens' partnership with Exact Sciences to promote colorectal cancer screening is another positive development.
Hedge funds are selling the stock, with a 614.09% increase in selling activity over the last quarter. Analysts have downgraded the stock to 'In Line' from 'Outperform,' and there is no recent congress trading activity to indicate confidence from influential figures.
In Q4 2025, revenue increased by 23.12% YoY to $878.38 million, but net income dropped by 90.06% YoY to -$85.96 million. EPS also declined by 90.36% YoY to -0.45, despite an improvement in gross margin to 70.11%, up 16.52% YoY.
Evercore ISI downgraded Exact Sciences to 'In Line' from 'Outperform,' with an unchanged price target of $105. This indicates a neutral stance from analysts.
